Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials

Medical writer: Tim Donald, ELS Rituximab plus lenalidomide (R2) demonstrated significant clinical benefit in two trials in patients with indolent non-Hodgkin lymphoma (iNHL), according to abstracts to be presented during a Poster Session on June 3. David Jacob Andorsky, MD, of Rocky Mountain Cancer Centres, US Oncology Research, will present interim analyses of the MAGNIFY trial (Abstract 7513). John G. Gribben, MD, Dsc, FRCP, FRCPath, FMedSci, of the Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, will present analyses of results from the AUGMENT trial (Abstract 7514). Both trials included patients with previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). The presentations are timely, as the U.S. Food and Drug Administration approved the use of lenalidomide in combination with rituximab for previously treated FL and previously treated MZL in the week before...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 15 July, 201925 March, 2021